Shares of Canada's Medicure shot up 23 percent this morning after the drug developer said that its experimental drug for hypertension and diabetes met primary blood pressure and metabolic endpoints in a Phase II study. "The MATCHED trial has exceeded our expectations, demonstrating the clinical benefits of MC-4232," CEO Albert Friesen said. Report